Glycosylation and Uraemia

Bruns, D E; Wills, M. R.

doi:10.1016/s0140-6736(84)92705-3

Cited by 4 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presumably, hemoglobin species modified by reactants other than glucose and not displaying a cis-1,1-diol group should not interfere with measurement of HbA 1c by boronate affinity methods. Published data support this lack of interference of carbHb with boronate affinity methods [6,16,17]. Therefore, we used the boronate affinity ultra 2 HPLC (Trinity Biotech) as our comparative method.…”

Section: Methodsmentioning

confidence: 94%

See 1 more Smart Citation

Measurement of Hba1C in patients with chronic renal failure

Little

Rohlfing

Tennill

et al. 2013

Clinica Chimica Acta

View full text Add to dashboard Cite

Background Carbamylated hemoglobin (carbHb) is reported to interfere with measurement and interpretation of HbA1c in diabetic patients with chronic renal failure (CRF). There is also concern that HbA1c may give low results in these patients due to shortened erythrocyte survival. Methods We evaluated the effect of carbHb on HbA1c measurements and compared HbA1c with glycated albumin (GA) in patients with and without renal disease to test if CRF causes clinically significant bias in HbA1c results using 11 assay methods. Subjects included those with and without renal failure and diabetes. Each subject’s estimated glomerular filtration rate (eGFR) was used to determine the presence and degree of renal disease. A multiple regression model was used to determine if the relationship between HbA1c results obtained from each test method and the comparative method were significantly (p<0.05) affected by eGFR. These methods were further evaluated for clinical significance using difference between the eGRF quartiles of >7% at 6 or 9% HbA1c. The relationship between HbA1c and glycated albumin (GA) in patients with and without renal failure was also compared. Results Some methods showed small but statistically significant effects of eGFR; none of these differences were clinically significant. If GA is assumed to better reflect glycemic control, then HbA1c was approximately 1.5% HbA1c lower in patients with renal failure. Conclusions Although most methods can measure HbA1c accurately in patients with renal failure, healthcare providers must interpret these test results cautiously in these patients due the propensity for shortened erythrocyte survival in renal failure.

show abstract

Section: Methodsmentioning

confidence: 94%

“…We therefore used eGFR as an indicator of overall renal function in place of direct measurement of carb Hb. We used a boronate affinity chromatography HPLC method as our reference method since this method has been shown to have no interference from carbHb [6,7,16,17]. …”

Section: Introductionmentioning

confidence: 99%

Measurement of Hba1C in patients with chronic renal failure

Little

Rohlfing

Tennill

et al. 2013

Clinica Chimica Acta

View full text Add to dashboard Cite

show abstract

“…Some of them found normal glycosylation values in uremic patients when using the TBA or affinity-chromatographic meth ods [19,25,31,33,34], but others like Haley and Ward [35] reported elevated levels of PGP determined with the TBA assay in hemodialysis and continuous peritoneal dialysis patients, while Bannon et al [36] also found 22% high GHb levels determined with the affinity chro matography method in hemodialysis patients and a dif ference in the GHb variances as compared with the nor mal group. These discrepancies are probably based on methodological differences: most works include few pa tients on conservative treatment, the range of renal func tion varies considerably among them, there are differ ences in the degree of anemia and blood transfusions received.…”

Section: Discussionmentioning

confidence: 99%

Nonenzymatic Glycosylation of Hemoglobin and Total Plasmatic Proteins in End-Stage Renal Disease

et al. 1991

View full text Add to dashboard Cite

In order to ascertain whether there are abnormalities of nonenzymatic glycosylation in uremia, the levels of nonenzymatically glycosylated hemoglobin (GHb), and total plasmatic glycosylated proteins (PGP) were studied using the thiobarbituric acid (TBA) method, a procedure not interfered with by carbamylation. Total hemoglobin A₁ (HbA₁) and the A_1c fraction were also determined by ion exchange chromatographic methods. Sixty-six end-stage renal disease patients (29 nondiabetic and 8 diabetic uremic patients on conservative treatment, 29 non-diabetic hemodialysis patients) and 56 controls (32 nonuremic diabetic patients and 24 healthy controls) were studied. High levels of GHb and total PGP were found in the nondiabetic uremic group on conservative treatment with all the methods used, but the persistence of high chromatographically determined HbA₁ levels in hemodialysis patients contrasts with the results obtained with the other techniques, which showed lower values on hemodialysis. Nondiabetic uremic patients with abnormal oral glucose tolerance curves had significantly higher levels of TBA-determined GHb and PGP. Uremic diabetic patients had the highest glycosylation levels of all the studied groups. We conclude that there is an abnormal nonenzymatic glycosylation of proteins in uremia, independent of carbamylation reactions and partially corrected by hemodialysis.

show abstract